Page 4 - Best Lung biopsy doctors: TOP 114 doctors

The doctor is a highly experienced oncologist with a focus on innovative cancer treatment methodologies. With over 15 years of clinical practice, the doctor has successfully treated a wide range of malignancies using cutting-edge therapies and personalized medicine approaches. The doctor is board-certified and has contributed to numerous peer-reviewed publications in oncology journals. Additionally, the doctor has been involved in several groundbreaking research projects aimed at improving patient outcomes and has presented findings at international conferences.

The doctor is an accomplished oncosurgeon with extensive experience in urology. As the Head of the Samsung Department of Urology, the doctor has led numerous innovative surgical procedures and contributed to significant advancements in the field. The doctor is recognized for expertise in minimally invasive techniques and has been instrumental in developing new protocols for cancer treatment. The doctor is highly regarded for a commitment to patient care and has received multiple accolades for contributions to medical research and education.

Dr. Adnan Sayar is a leading thoracic surgeon in Turkey. He has over 40 years of medical experience and more than 30 years in thoracic surgery. He is known for his work in minimally invasive thoracoscopic and robotic procedures. These techniques have helped improve patient recovery and outcomes for chest diseases.

Dr. Sayar received international training at top centers, including Kyoto University and the Karolinska Institute. He is a key figure in lung transplantation and serves on Turkey’s Ministry of Health Lung Transplantation Scientific Committee. He also holds the FETCS certification from the European Board of Thoracic and Cardiovascular Surgery.

His expertise includes lung cancer surgery, tracheal and diaphragmatic reconstruction, and pediatric thoracic surgery. As a professor and mentor, he has led both public and private institutions. Dr. Sayar has helped thousands of patients and has played a major role in advancing thoracic care standards in Turkey.

Medical Fields of Interest 

• Thoracoscopic and Robotic Minimally Invasive Surgery 

• Lung Cancers 

• Trachea Surgery 

• Lung Transplantation 

• Lung Biopsy • Pneumothorax (collapsed lung) 

• Diaphragmatic Surgery • Surgery of Pleural Diseases 

• Pediatric Thoracic Surgery

Education 

• Istanbul University, Istanbul Faculty of Medicine 

•Istanbul Galatasaray High School 

• Primary Education Ankara, Samsun, Izmir 

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

Medical Intrests

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Rectal Cancer
• Ovarian Cancer
• Liver Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Kidney Cancer
• Larynx Cancer - Cancer of the Larynx
• Thyroid Cancer
• Head and Neck Cancers
• Gynaecological Cancers
• Pancreatic Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Uterine Cancer
• Brain Cancers - Brain Tumours
• Soft Tissue Cancer - Sarcomas
• Prostate Cancer
• Bladder Cancer
• Bile Tract Cancer
• Testicular Cancer
• Cervical Cancer
• Mouth, Tongue, Lip Cancers
• Gastrointestinal System Cancers
• Bone Tumours
• Trachea and Bronchial Cancers
• Skin Cancers - Skin Cancers
• Skeletal System Tumours
• Gallbladder Cancer
• Mesothelioma

The doctor completed specialization training in Radiation Oncology at Marmara University Faculty of Medicine from 2012 to 2016. Prior to this, the doctor completed an undergraduate degree in Medicine, taught in English, at the same institution from 2004 to 2011. The doctor has a strong foundation in medical education, beginning with high school education at Sixteen Numbered Shirvan School in Azerbaijan from 1998 to 2004.

The doctor is a seasoned General Surgeon at Anadolu Medical Center with 23 years of experience. Specializing in General Surgery, Surgical Infections, Breast Cancer, Thyroid/Parathyroid Surgery, and Advanced Minimally Invasive Surgery, the doctor also focuses on Pancreatic Cancer and Glucose Metabolism. Graduating from Hacettepe University School of Medicine in 1990, the doctor completed specialization training in General Surgery in 1996. Actively associated with numerous professional organizations, the doctor has authored 31 international and 22 national publications, contributing significantly to medical literature.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

The doctor received Surgical Oncology training at Tata Memorial Hospital, Mumbai, and completed MRCS at the Royal College of Surgeons, Edinburgh. Starting practice in 2000, the doctor founded Curie Manavata Cancer Centre in 2007. With 19 years of experience, the doctor has performed over 50,000 cancer surgeries and participated in more than 200 clinical trials. The doctor is a published author with numerous international and national publications. Specializing in Breast and Thoracic Surgical Oncology, the doctor is a professor for DNB Superspecialty Surgical Oncology and Breast Surgery at MUHS.

The doctor graduated from Uludağ University Medical College with a Diploma of Medicine in 1983 and completed a residency in Radiation Oncology at the Center of Oncology & Nuclear Medicine in Istanbul in 1990. A post-doctoral fellowship in Thermoradiotherapy was completed at Thomas Jefferson University from 1990 to 1994. The doctor served as Professor and Chairman of the Department of Radiation Oncology at Uludağ University Medical College from 1994 to 2005 and was the Faculty Accreditation Coordinator from 2001 to 2004.

From 2004 to 2017, the doctor was a Professor and Director of the Department of Radiation Oncology at Anadolu Medical Center, also serving as Coordinator of Oncological Sciences from 2011 to 2017. Currently, the doctor is the Director of Oncological Sciences at Medicana Bursa Hospital, a position held since 2018.

The doctor is a board-certified oncologist with over 15 years of experience in the field of medical oncology. Specializing in the treatment of breast and lung cancers, the doctor has contributed to numerous clinical trials aimed at developing innovative cancer therapies. The doctor has published over 50 peer-reviewed articles in prestigious medical journals, advancing the understanding of cancer treatment protocols. Additionally, the doctor is a member of several leading oncology societies and has been a keynote speaker at international oncology conferences.

The doctor completed an MBBS from MIMER, Pune, and an MS from GMC Panaji. Further training included a two-year fellowship in Surgical Oncology at Tata Medical Centre, Kolkata, focusing on Gastrointestinal Cancer. At Tata Medical Center, the doctor served as a Co-principal Investigator in multiple original research projects. Following this, the doctor worked as an Assistant Professor at the State Cancer Institute and Government Cancer Hospital, Aurangabad. With over 10 years of experience, the doctor has successfully performed more than 10,000 major surgeries and has published multiple National and International papers. Specializes in Minimal Invasive Cancer Surgeries.

The doctor is an MDS in Oral & Maxillofacial Surgery with 3 years of experience in Surgical Oncology at the HCG Manavata Cancer Centre in Nasik.

Specializes in oral cancer, focusing on organ preservation and functional rehabilitation. Has a strong interest in preventive oral hygiene and early diagnosis of oral cancers.

Proficient in major maxillofacial and head & neck surgeries and has completed fellowship training in Head & Neck Surgical Oncology from HCG Manavata Cancer Centre.

Active researcher with numerous publications.

The doctor is a highly skilled oncologist specializing in the treatment of various cancer types, including solid tumors, pediatric tumors, and hematological malignancies. She is proficient in both conservative and surgical treatments, such as the Whipple procedure.

She completed her MBBS at Lady Hardinge Medical College and MD in internal medicine from Maulana Azad Medical College. She further pursued DM Medical Oncology at Tata Memorial Hospital, where she also served as a consultant.

She is affiliated with international and national oncological societies and has expertise in lung, breast, gynecological, and genitourinary cancers, with a keen interest in immunotherapy and metronomic therapy.

The doctor is an experienced nuclear medicine specialist at HCG Manavata Cancer Centre with 12 years in the field. The doctor specializes in various nuclear scans, PET-CT scans, and nuclear cardiology services, demonstrating proficiency in radioiodine and Lu-177 RN therapies. Over the course of their career, the doctor has managed more than 30,000 PET scans and treated over 1,000 thyroid cancer patients. Additionally, the doctor has contributed to the field through published papers in various medical journals.

The doctor graduated with a Bachelor of Medicine from Mysore University in 1996, followed by a Doctor of Medicine in radiotherapy from Banaras Hindu University in 2002. Further enhancing expertise, the doctor earned a Diplomate of National Board in radiotherapy in 2004.

The doctor is a member of several prestigious organizations, including the Association of Radiation Oncology of India, the Society for Neuro-Oncology, the Bangalore Oncology Group, and the Indian Association of Hyperthermia Oncology, reflecting a strong commitment to advancing the field of oncology.

The doctor is an accomplished oncologist with a focus on innovative cancer treatments and research. As the Head of the Center of Oncology at Charite, the doctor leads a team dedicated to advancing oncology care and improving patient outcomes through cutting-edge therapies and clinical trials. With a strong commitment to education and research, the doctor has contributed significantly to the field of oncology, participating in numerous high-impact studies and publications.

The doctor is an accomplished educator and researcher in the field of oncology, with extensive teaching experience at USP CEU. The doctor has taught a wide array of subjects including General Medical Pathology, Oral and Maxillofacial Oncology, and Bioethics. As a tutor for medical students and external rotants, the doctor has contributed significantly to the training of future healthcare professionals.

Additionally, the doctor holds the position of Director of postgraduate research in clinical and applied oncology at HM CIOCC USP CEU and is responsible for postgraduate master practices. The doctor has also completed advanced courses at MD Anderson Cancer Center.